The Eli Lilly and Company will acquire Adverum Biotechnologies, according to a joint press release issued by the 2 companies.

Second-generation anti-VEGF agents, like aflibercept 8 mg and faricimab, show improved efficacy and treatment durability in ...

The Phase 2 OptimUM-09 trial shows promising results for uveal melanoma, addressing the lack of approved systemic therapies. Significant tumor size reduction and improved visual acuity were observed ...

Regeneron has once again received a complete response letter (CRL) from the US Food and Drug Administration (FDA) for the ...

To celebrate Ophthalmology Times' 50th anniversary, we asked leading experts what the practice would look like today had ...

Over the span of modern ophthalmic practice, few specialties have experienced as much transformation as corneal and anterior ...

In the week following the announcement of this acquisition, Sanro Health, Inc. is reported to have made an investment in ...

From MIGS integration to remote monitoring and next-generation therapeutics, glaucoma specialists explore how new approaches ...

The conversation included these specialists in cataract and refractive surgery: Eric D. Donnenfeld, MD, clinical professor of ophthalmology at New York University Medical Center, New York, NY, and ...

Leonard K. Seibold, MD, is Professor of Ophthalmology, Glaucoma Service Chief and Fellowship Director, University of Colorado School of Medicine. Seibold consults for AbbVie, New World Medical, and ...

Kateki Vinod, MD, is Associate Professor of Ophthalmology, Icahn School of Medicine at Mount Sinai, New York Eye and Ear Infirmary of Mount Sinai. Vinod has no financial disclosures.

The lesion characteristics of patients with geographic atrophy (GA) were found to affect the lesion growth rate, with ...